ArticleFrontiers in bioengineering and biotechnology2026
Efficacy of the combination of umbilical fat and venous blood on limb salvage.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy of combined umbilical adipose tissue and venous blood-derived stromal vascular fraction (SVF) on limb perfusion, pain and functional recovery in patients with chronic limb-threatening ischemia (CLTI). Methods: A total of 20 patients aged between 36 and 82 years (mean age: 60.3 ± 11.2 years) were included in the study. Ankle-Brachial Index (ABI), pain scores and pain-free walking distance were evaluated before treatment and at follow-up at 3, 6, 9 and 12 months. Results: At 12 months, ABI increased significantly, Visual Analog Scale (VAS) decreased, while pain-free walking distance improved at 9 and 12 months compared to baseline. Left ventricular ejection fraction (LVEF) showed a non-significant rise (54.6%-55.2%, p = 0.072), while renal function improved modestly (creatinine 1.12 → 1.09 mg/dL, eGFR 78 → 80.5 mL/min/1.73 m Conclusions: Combined Autologous conditioned plasma (ACP) and adipose-derived SVF injections effectively improved limb perfusion, pain, lesion severity and functional outcomes in CLTI patients, suggesting a promising therapeutic approach for peripheral arterial disease (PAD).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.